Breath analysis
A group of scientists in Austria 1 have developed and characterised a method for the detection of S. pneumoniae and H. influenzae in the upper respiratory tract by analysing breath samples of patients.
Steptococcus pneumoniae and Haemophilus influenzae are the causative agents of community-associated pneumonia (CAP). CAP is principally responsible for the highest number of deaths resulting from bacterial infection. The illness mainly infects young adults, children and those who are immunocompromised because of a pre‑existing condition, such as patients prescribed with immunosuppressant drugs following organ transplantation. This group of patients are therefore unlikely to be comfortable undergoing current diagnostic tests that are considered invasive and slow to the point that the infection can become more advanced. This increases the demand for a non-invasive, rapid and economic test that can pinpoint the presence of infection before it can progress.
A group of scientists in Austria 1 have developed and characterised a method for the detection of S. pneumoniae and H. influenzae in the upper respiratory tract by analysing breath samples of patients. Using gas chromatography coupled to mass spectrometry (GC–MS), the investigators identified a broad spectrum of volatile organic compounds (VOCs) associated with the two infections. Headspace samples were adsorbed to multi‑bed sorption tubes prior to GC–MS analysis. The analysis resulted in the identification of 34 VOCs released from S. pneumoniae and 28 VOCs released from H. influenzae and interestingly for S. pneumoniae catabolism of aldehydes was detected.
These initial findings of differential chemical profiles associated with the two different respiratory infections indicate that there is the opportunity for the development of a portable breath gas analyser that may be less invasive and intrusive than current diagnostic methods. Further investigations are required to increase the sample number of patients and to eliminate patient variability.
1. A. Ammann et al, Microbiology, DOI: 10.1099/mic.0.0626870 (2012).
This story originally appeared in The Column. Click here to view that issue.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
Inside the Laboratory: The Richardson Group at the University of South Carolina
November 20th 2024In this edition of “Inside the Laboratory,” Susan Richardson of the University of South Carolina discusses her laboratory’s work with using electron ionization and chemical ionization with gas chromatography–mass spectrometry (GC–MS) to detect DBPs in complex environmental matrices, and how her work advances environmental analysis.
